Skip to content

The effect of an extended use of enteral tube feeding sets on growth of microorganisms

The effect of an extended use of enteral tube feeding sets on growth of microorganisms - EXTENSION

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON57181
Enrollment
45
Registered
2024-10-10
Start date
2025-08-19
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroenteritis gastroenteritis

Interventions

Extended use of an enteral tube feeding set from 24 hours to 96 hours

Sponsors

Medisch Spectrum Twente (MST)
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Mentally competent Age 18 years or older Treatment with continuous enteral feed is expected to last for at least 96hrs from inclusion (minimum 20ml/hr) Gastric/ jejunal tube inserted during current hospital admission ICU patients: treated with Selective Digestive Decontamination (SDD) which implies expected mechanical ventilation for more than 48 hours.

Exclusion criteria

Exclusion criteria: Inability to feed enteral due to gastro-intestinal disease Patients with severe gastro-enteritis (according to doctor*s opinion), chronic abdominal bowel disease Patients with immune system disorders Palliative care

Design outcomes

Primary

MeasureTime frame
The amount of enteral tube feeding sets contaminated with microorganisms

Secondary

MeasureTime frame
The number of contaminated tube feeding sets related to patient cultures (retrieved from regular patient care) contaminated with the same microorganism(s). The number of patients with gastrointestinal events (i.e. diarrhea, vomiting, nausea, abdominal pain) and new onset of sepsis; The influence of SDD on the number of gastro-intestinal events and the growth of microorganisms in enteral tube feeding sets; The percentage of enteral tube feeding sets that did not endure 96 hours of use, according to the durability checklist (appendix II); Number of (serious) adverse events ((S)AE's).

Countries

Netherlands

Contacts

Public ContactM Bos-Burgmeijer

Medisch Spectrum Twente (MST)

m.burgmeijer@mst.nl+31 6 21142632

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Aug 9, 2026